Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
NLNK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading NLNK News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.64%68.221.0%$511.57m
AMGNAmgen Inc.
-0.06%164.611.2%$473.08m
BIIBBiogen Inc.
-2.41%279.981.2%$433.18m
CELGCelgene Corporation
-0.26%125.201.1%$368.74m
REGNRegeneron Pharmaceuticals, Inc.
-0.25%371.392.7%$306.45m
VRTXVertex Pharmaceuticals Incorporated
-0.79%116.341.8%$289.18m
INCYIncyte Corporation
-1.05%123.082.1%$252.04m
ALXNAlexion Pharmaceuticals, Inc.
0.15%120.731.6%$213.99m
ILMNIllumina, Inc.
1.70%184.583.3%$188.12m
TSROTESARO, Inc.
2.58%142.0115.3%$145.06m
NBIXNeurocrine Biosciences, Inc.
-0.63%53.284.5%$109.21m
BMRNBioMarin Pharmaceutical Inc.
2.00%96.074.3%$103.70m
KITEKite Pharma, Inc.
2.77%82.8015.6%$98.74m
CLVSClovis Oncology, Inc.
1.35%58.6418.2%$88.77m
AAgilent Technologies, Inc.
0.06%54.841.6%$88.10m

Company Profile

NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.